Psychedelic Stocks & Companies

A directory of public and private companies active in the psychedelic space.

Looking to invest in companies at the forefront of psychedelic research, development, and production? On this page we collect the shroom stock options available to members of the public, and private companies that may present investment opportunities in the future.

 

***

Publicly Listed Psychedelic Stocks & Companies

There are a growing number of psychedelic companies that are actively researching and developing psychedelics for medical and therapeutic purposes. Below is a directory of these mushroom stocks, in no particular order. Where possible, we have offered a stock quote: please note that these are in USD where possible, for comparative purposes (and thus generally represent the OTC ticker).

MindMed (NEO: MMED)

OTC: MMEDF | USD $1.71 | +7.29%

MindMed is a psychedelic medicine company with a primary focus on using formulations of Ibogaine and LSD to treat mental health issues. Their current pipeline features 18-MC (derived from Ibogaine) and LSD microdosing.

Visit our MindMed Company Profile to learn more.

NEO: MMED | OTC: MMEDF | FWB: BGHM

Champignon Brands Inc. (CSE: SHRM)

OTC: SHRMF | USD $0.49 | -5.22%

Champignon Brands is a publicly-traded, research-driven company active in the formulation and production of a variety of psychedelic medicines and products.
 
Champignon has acquired a ketamine clinic in California, and intends to continue its North American expansion. Read our interview with Champignon CEO, Dr. Roger McIntyre.
 
Visit our Champignon Company Profile to learn more.
 
CSE: SHRM | OTC: SHRMF | FWB: 496
 

Compass Pathways (NASDAQ: CMPS)

NASDAQ: CMPS | USD $47.45 | +16.21%

UK-based Compass Pathways are one of the most prolific players in the emergent psilocybin space, actively conducting clinical trials to demonstrate the safety of psilocybin, and its potential to tackle treatment-resistant depression.

Compass IPO’d on Friday 18th September, 2020, on the Nasdaq.

The US Food and Drug Administration (FDA) awarded a “Breakthrough Therapy” designation to Compass for their research into the use of psilocybin for severe depression. This allows the Company to accelerate the (usually very slow) development and review of their drugs. Typically, such a designation is only approved where early evidence suggests the drug in question could pose a significant improvement versus currently-available therapy.

Compass has conducted, and is conducting, a range of registered clinical trials across the world. In the United Kingdom, the Company has worked with the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London to successfully conduct a double-blind, placebo-controlled study with nearly ninety participants between 18-65 years of age. The study found that psilocybin was well-tolerated by the healthy adult volunteers.

Compass Pathways has some well-known investors, including Peter Thiel (PayPal co-founder).

Visit our Compass Pathways Company Profile to learn more.

Nasdaq: CMPS
 

Field Trip Health, Inc. (CSE: FTRP)

OTC: FTRPF | USD $3.72 | -2.58%

Field Trip is a mental wellness company that focuses on psychedelics and psychedelic-enhanced psychotherapy. In February 2020 they closed their Series A funding round, having raised $8.5m USD. The Company listed on the CSE on 6th Oct, 2020.

Visit our Field Trip Company Profile to learn more.

CSE: FTRP | OTC: FTRPF
 

Numinus (TSXV: NUMI)

OTC: LKYSF | USD $0.55 | +1.92%

Numinus listed on TSXV on Wednesday 20th May, 2020.

Numinus is licensed, via Salvation Botanicals, by Health Canada to test, sell and distribute psychedelic substances. You can read our interview with CMO Dr. Evan Wood here.

In October 2020, Numinus harvested their first flush of Psilocybe mushrooms, a milestone for the sector.

Visit our Numinus Company Profile to learn more.

TSXV: NUMI | OTC: LKYSF

Cybin Corp (NEO: CYBN)

Cybin announced a planned reverse takeover (RTO) in late June 2020. Once completed, the Company should become publicly traded.

In October 2020 Cybin announced the closing of a $45 million raise, the largest funding round for a psychedelic company in Canadian history.

The Company plans to list on the NEO Exchange.

Visit our Cybin Corp Company Profile to learn more.

NEO: CYBN

HAVN Life Sciences (CSE: HAVN)

OTC: HAVNLF

HAVN Life Sciences  is a biotechnology company focused on standardized, quality-controlled extraction of psychoactive compounds from plants and fungi, and the development of natural health care products from non-regulated compounds. They went public in September 2020.

Visit our Havn Life Company Profile to learn more.

CSE: HAVN | OTC: HAVNLF

Entheon Biomedical (CSE: ENBI)

Entheon Biomedical is a biotech company focussed on the development of psychedelic medicines for addiction disorders. The Company’s research and development pipeline revolves around DMT.

The Company listed on the CSE on 12 November, 2020.

Visit our Entheon Company Profile to learn more.

CSE: ENBI

Better Plant Sciences (CSE: PLNT) 

OTC: VEGGF | USD $0.05 | -2.88%

In August 2020 Yield Growth Corp. announced a name change to Better Plant Sciences.

The Company has a portfolio of over 100 psilocybin formulas via its subsidiary, Flourish Mushroom Labs. 

Flourish has formed of a Company in Saint Vincent and the Grenadines, Acres Flourish Labs, which plans to construct a purpose-built laboratory for the cultivation of psilocybin mushrooms, and for R&D activities.

Flourish also acquired a founding interest in Translational Life Sciences Inc., a biotechnology company seeking to develop formulas containing restricted substances (such as cannabis and psilocybin) that may have medical applications.

Flourish has already begun to file provisional US patents for their psilocybin ‘treatments’, including the administering of psilocybin/psilocin microdoses in order to encourage weight loss via the increase of metabolism and limiting of food cravings.

Visit our Better Plant Sciences Company Profile to learn more.

CSE: PLNT | OTC: VEGGF | FWB: YG3

Revive Therapeutics Ltd. (CSE: RVV)

OTC: RVVTF | USD $0.23 | +6.90%

Revive Therapeutics is focused on the R&D and sale of cannabinoid-based products, and has completed a Letter of Intent to acquire Psilocin Pharma Corp.

Psilocin has developed, and plans to continue developing, production solutions for Psilocybin. Boasting six formulations thus far, the company has ambitions to begin selling their psilocybin products in countries like Brazil where they are legally approved. Ultimately, they plan to access the US clinical market, pending FDA approvals.

Visit our Revive Therapeutics Company Profile to learn more.

CSE: RVV | OTC: RVVTF 

M2BIO (OTC: WUHN)

OTC: WUHN | USD $0.39 | +20.25%

M2BIO was formerly known as Wuhan General Group, changing their name in June 2020.

Wuhan General Group is a Chinese alternative medicine company with a clear focus on CBD and psilocybin. 

OTC: WUHN

Mind Cure Health Inc. (CSE: MCUR)

OTC: MCURF | USD $0.50 | +23.79%

Mind Cure is primarily focussed on microdosing.

The Company conducted an IPO in September 2020, and began trading publicly on the CSE on 21st September, 2020.

CSE: MCUR | OTC: MCURF

Mydecine Innovations Group (CSE: MYCO)

OTC: MYCOF | USD $0.24 | +10.02%

Mydecine Innovations Group is a publicly traded life sciences syndicate. The Company’s portfolio includes natural health products, research and development, and digital health solutions.

NewLeaf Brands changed its name to Mydecine in June 2020. NewLeaf was a CBD lifestyle company, that then expanded into the shroom space. In May 2020, the company announced that  Mydecine Group, is building-out a specialist mycology lab in Denver, Colorado.

Visit our Mydecine Company Profile to learn more.

CSE: MYCO | OTC: MYCOF | FWB: 0NF

Hollister Biosciences (CSE: HOLL)

OTC: HSTRF | USD $0.09 | -0.22%

Canadian cannabis firm Hollister Biosciences entered into a definitive agreement to acquire Alphamind Brands, and closed the acquisition in April 2020. Alphamind are conducting R&D into psilocybin-based drug therapies, seeking to build an IP portfolio in the psychedelic medicine space. 

Visit our Hollister Biosciences Company Profile to learn more.

CSE: HOLL | OTC: HSTRF | FWB: HOB

New Wave Holdings (CSE: SPOR)

OTC: TRMND | USD $0.05 | +19.50%

New Wave is exploring recreational, natural (functional) and mental health applications of psychedelics. The company has two production facilities in Jamaica (via its 50% interest in Anahit International Corp.) licensed for mushroom cultivation, and is building a psilocybin-based IP portfolio. 

CSE: SPOR | OTC: TRMND | FWB: 0XM2

GreenStar Biosciences (CSE: GSTR)

OTC: GTSIF | USD $0.05 | -0.27%

GreenStar has thus far predominantly focused on supporting licensed cannabis businesses in the US, but recently they announced the acquisition of Toronto-based Eleusian Biosciences. The Company described the acquisition as opening access to the emerging psychedelic medicine sector, as Elusian has already undertaken work on psilocybin, having filed a provisional patent application for its combined usage in addressing mild traumatic brain injury and PTSD.

CSE: GSTR | OTC: GTSIF 

Thoughtful Brands (CSE: TBI)

OTC: PEMTF | USD $0.06 | +3.70%

Note: In August 2020, Mota Ventures changed their name to Thoughtful Brands Inc.

Mota is a CBD producer, exporter and distributor. In May 2020, Mota announced that they were acquiring a Germany psilocybin manufacturer.

CSE: TBI | OTC: PEMTF | FWB: 1WZ1

Silo Wellness (Coming Soon)

In June 2020, Silo Wellness announced a proposed RTO of Yukoterre Resources, meaning it may trade publicly soon.

Aion Therapeutic (CSE: AION)

Note: in August 2020, Osoyoos Cannabis Inc. changed its name to Aion Therapeutic Inc.

Osoyoos is, as the name suggests, a company primarily associated with the cannabis space. In June 2020, the Company announced the proposed acquisition of AI Pharmaceuticals Jamaica Limited, who are engaged in the R&D of cannabis and psilocin-based pharmaceutical, nutraceutical and cosmeceutical formulations and related IP.

CSE: AION | OTC: ANTCF

Ehave Inc (OTC: EHVVF)

OTC: EHVVF | USD $0.03 | -8.00%

Ehave Inc provides digital therapeutics such as mental health informatics platforms. The company hopes to provide its services to the psychedelic medicine sector. 

OTC: EHVVF

Red Light Holland (CSE: TRIP)

OTC: TRUFF | USD $0.10 | +29.47%

Red Light Holland is seeking to capitalise on the existing recreational market in the Netherlands, selling magic truffles via Smart Shops and an e-commerce platform.

CSE: TRIP | OTC: TRUFF

Roadman Investments Corp. (TSXV: LITT)

OTC: RAMNF

Roadman Investments Corp. is a Canadian Venture Capital and Advisory Firm. They have invested in a variety of companies in a range of sectors: from fintech to agriculture.

TSXV: LITT | OTC: RMANF | FWB: 1QD

Lobe Sciences (CSE: LOBE)

Lobe Sciences undertook a rebrand in November 2020 to shift toward the psychedelic medicine sector. The Company acquired Eleusian Biosciences, a psychedelic medicine development company.

CSE: LOBE | OTC: GTSIF

 

***

Private Companies in the Psychedelic Space

The following companies have demonstrated interest (to varying degrees) in the psychedelic space.

As with the publicly-traded psilocybin stocks above, many of the companies below have an existing base in the cannabis sector.

ATAI Life Sciences

ATAI is a global biotechnology ‘company builder’, seeking to acquire and develop mental health treatments. With tentacles in Berlin, New York and Amsterdam, ATAI has raised large amounts of backing to finance research into psychedelic medicines for depression and other mental illnesses.

ATAI Life Sciences owns a large stake in Compass Pathways (above), after investing in their Series A round.

Visit out ATAI Life Sciences Company Profile to learn more.

Beckley Psytech

The founders of Beckley Psytech hail from one of the most established think tanks / NGOs in the psychedelic medicine space: The Beckley Foundation

The Company is building a pipeline of psychedelic compounds for a variety of mental and neurological diseases.

Visit our Beckley Psytech Company Profile to learn more.

Eleusis

Founded in 2013, Eleusis is one of the early movers in the psychedelic medicine space, with a two-pronged approach harnessing psychedelics for both anti-inflammatory and mental health applications. Learn more in our interview with Shlomi Raz, CEO and chairman.

Visit our Eleusis Company Profile to learn more.

CaaMTech

CaaMTech is a drug discovery company with a focus on engineering psychedelic drugs, including psilocybin. You can read our interview with CaaMTech here.

Visit our CaaMTech Company Profile to learn more.

Orthogonal Thinker

Orthogonal have demonstrated serious interest in psilocybin, and look set to pursue intellectual property protection of their plant-derived psilocybin product ‘Psilly’. Beyond this, the company focuses on CBD, hemp, cannabis, food as medicine, and other nutritional alkaloids.

Orthogonal has some interesting plans for how to improve the process of synthesizing psilocybin, including the employment of blockchain and artificial intelligence (AI).

In their summary of goals and plansOrthogonal included the prospect of partnering with, or purchasing, a laboratory to research and develop DEA-registered psilocybin.

In December 2019, the Company launched PsillyLife, which they tout as ‘the first psychedelics lifestyle brand’. The brand seeks to disseminate the benefits of psilocybin to a global audience, all via a laid-back Hawaiian aesthetic. Take a look at their website to see what we mean here.m

MagicMed Industries

MagicMed is a private Canadian company seeking to build a molecular derivatives patent library, dubbed the Psybrary™, which is initially focused on psilocybin. In September 2020 the Company closed a $1.6m private placement at $0.25 per share.

MagicMed are also a founding member of the Psychedelic Medicine Association.

Visit our MagicMed Company Profile to learn more.